R B Laprairie1, A M Bagher1, M E M Kelly1,2, E M Denovan-Wright1. 1. Departments of Pharmacology, Dalhousie University, Halifax, NS, Canada. 2. Opthamology and Visual Sciences, Dalhousie University, Halifax, NS, Canada.
Abstract
BACKGROUND AND PURPOSE: Cannabidiol has been reported to act as an antagonist at cannabinoid CB1 receptors. We hypothesized that cannabidiol would inhibit cannabinoid agonist activity through negative allosteric modulation of CB1 receptors. EXPERIMENTAL APPROACH: Internalization of CB1 receptors, arrestin2 recruitment, and PLCβ3 and ERK1/2 phosphorylation, were quantified in HEK 293A cells heterologously expressing CB1 receptors and in the STHdh(Q7/Q7) cell model of striatal neurons endogenously expressing CB1 receptors. Cells were treated with 2-arachidonylglycerol or Δ(9)-tetrahydrocannabinol alone and in combination with different concentrations of cannabidiol. KEY RESULTS: Cannabidiol reduced the efficacy and potency of 2-arachidonylglycerol and Δ(9)-tetrahydrocannabinol on PLCβ3- and ERK1/2-dependent signalling in cells heterologously (HEK 293A) or endogenously (STHdh(Q7/Q7)) expressing CB1 receptors. By reducing arrestin2 recruitment to CB1 receptors, cannabidiol treatment prevented internalization of these receptors. The allosteric activity of cannabidiol depended upon polar residues being present at positions 98 and 107 in the extracellular amino terminus of the CB1 receptor. CONCLUSIONS AND IMPLICATIONS: Cannabidiol behaved as a non-competitive negative allosteric modulator of CB1 receptors. Allosteric modulation, in conjunction with effects not mediated by CB1 receptors, may explain the in vivo effects of cannabidiol. Allosteric modulators of CB1 receptors have the potential to treat CNS and peripheral disorders while avoiding the adverse effects associated with orthosteric agonism or antagonism of these receptors.
BACKGROUND AND PURPOSE:Cannabidiol has been reported to act as an antagonist at cannabinoidCB1 receptors. We hypothesized that cannabidiol would inhibit cannabinoid agonist activity through negative allosteric modulation of CB1 receptors. EXPERIMENTAL APPROACH: Internalization of CB1 receptors, arrestin2 recruitment, and PLCβ3 and ERK1/2 phosphorylation, were quantified in HEK 293A cells heterologously expressing CB1 receptors and in the STHdh(Q7/Q7) cell model of striatal neurons endogenously expressing CB1 receptors. Cells were treated with 2-arachidonylglycerol or Δ(9)-tetrahydrocannabinol alone and in combination with different concentrations of cannabidiol. KEY RESULTS:Cannabidiol reduced the efficacy and potency of 2-arachidonylglycerol and Δ(9)-tetrahydrocannabinol on PLCβ3- and ERK1/2-dependent signalling in cells heterologously (HEK 293A) or endogenously (STHdh(Q7/Q7)) expressing CB1 receptors. By reducing arrestin2 recruitment to CB1 receptors, cannabidiol treatment prevented internalization of these receptors. The allosteric activity of cannabidiol depended upon polar residues being present at positions 98 and 107 in the extracellular amino terminus of the CB1 receptor. CONCLUSIONS AND IMPLICATIONS: Cannabidiol behaved as a non-competitive negative allosteric modulator of CB1 receptors. Allosteric modulation, in conjunction with effects not mediated by CB1 receptors, may explain the in vivo effects of cannabidiol. Allosteric modulators of CB1 receptors have the potential to treat CNS and peripheral disorders while avoiding the adverse effects associated with orthosteric agonism or antagonism of these receptors.
Authors: E Ryberg; N Larsson; S Sjögren; S Hjorth; N-O Hermansson; J Leonova; T Elebring; K Nilsson; T Drmota; P J Greasley Journal: Br J Pharmacol Date: 2007-09-17 Impact factor: 8.739
Authors: Robert B Laprairie; Jordan R Warford; Sarah Hutchings; George S Robertson; Melanie E M Kelly; Eileen M Denovan-Wright Journal: J Neuroimmunol Date: 2013-12-12 Impact factor: 3.478
Authors: Robert B Laprairie; Amina M Bagher; Melanie E M Kelly; Denis J Dupré; Eileen M Denovan-Wright Journal: J Biol Chem Date: 2014-07-18 Impact factor: 5.157
Authors: Brian D Hudson; Elisabeth Christiansen; Hannah Murdoch; Laura Jenkins; Anders Højgaard Hansen; Ole Madsen; Trond Ulven; Graeme Milligan Journal: Mol Pharmacol Date: 2014-05-28 Impact factor: 4.436
Authors: Francesco Piscitelli; Alessia Ligresti; Giuseppe La Regina; Antonio Coluccia; Ludovica Morera; Marco Allarà; Ettore Novellino; Vincenzo Di Marzo; Romano Silvestri Journal: J Med Chem Date: 2012-05-17 Impact factor: 7.446
Authors: Mason M Silveira; Jonathon C Arnold; Steven R Laviolette; Cecilia J Hillard; Marta Celorrio; María S Aymerich; Wendy K Adams Journal: Neurosci Biobehav Rev Date: 2016-09-14 Impact factor: 8.989
Authors: Hanna J Szkudlarek; Sagar J Desai; Justine Renard; Brian Pereira; Christopher Norris; Christina E L Jobson; Nagalingam Rajakumar; Brian L Allman; Steven R Laviolette Journal: Neuropsychopharmacology Date: 2018-11-27 Impact factor: 7.853
Authors: Tom P Freeman; Chandni Hindocha; Gianluca Baio; Natacha D C Shaban; Emily M Thomas; Danica Astbury; Abigail M Freeman; Rachel Lees; Sam Craft; Paul D Morrison; Michael A P Bloomfield; Dominic O'Ryan; Jane Kinghorn; Celia J A Morgan; Ali Mofeez; H Valerie Curran Journal: Lancet Psychiatry Date: 2020-07-28 Impact factor: 27.083
Authors: Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes Journal: Neurosci Biobehav Rev Date: 2017-05 Impact factor: 8.989